Retifanlimab Plus Chemotherapy Significantly Extends Overall Survival in First-Line Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial
Executive Highlights
The POD1UM-304 phase 3 trial marks a significant milestone in the management of metastatic non-small-cell lung cancer (NSCLC). The study successfully met its primary endpoint, demonstrating that the addition of retifanlimab, a PD-1 inhibitor, to standard-of-care platinum-based chemotherapy significantly prolongs overall survival (OS) compared to chemotherapy alone.
Key findings include a median OS of 18.1 months in the retifanlimab-chemotherapy group versus 13.4 months in the placebo-chemotherapy group (Hazard Ratio [HR] 0.75; p=0.0042).
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.